Article
The Difference in Clinical Outcomes Between Osimertinib and Afatinib for First-Line Treatment in Patients with Advanced and Recurrent EGFR-Mutant Non-Small Cell Lung Cancer in Taiwan.
Targeted oncology - 1 May 2022
Huang Yen-Hsiang, Hsu Kuo-Hsuan, Tseng Jeng-Sen, Yang Tsung-Ying, Chen Kun-Chieh, Su Kang-Yi, Yu Sung-Liang, Chen Jeremy J W, Chang Gee-Chen
Abstract excerpt
BACKGROUND: Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors are the standard first-line treatment for patients with advanced and recurrent EGFR-positive non-small cell lung cancer. OBJECTIVE: The main objective of the present study was to compare the clinical efficacies between osimertinib and afatinib as first-line treatment in patients with EGFR-mutant non-small cell lung cancer. METHODS: We...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.